 Vijaya Knight
Concepts (225)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunologic Deficiency Syndromes | 4 | 2023 | 69 | 2.300 |
Why?
| | Flow Cytometry | 5 | 2025 | 1185 | 1.970 |
Why?
| | Antibodies, Viral | 8 | 2022 | 623 | 1.650 |
Why?
| | Antibodies, Neutralizing | 3 | 2021 | 282 | 1.320 |
Why?
| | Cytokines | 4 | 2022 | 2095 | 1.190 |
Why?
| | Autoantibodies | 4 | 2022 | 1501 | 1.140 |
Why?
| | Laboratories | 3 | 2021 | 113 | 0.990 |
Why?
| | Immunoglobulin E | 3 | 2024 | 341 | 0.980 |
Why?
| | Immunoglobulin Class Switching | 1 | 2025 | 20 | 0.930 |
Why?
| | Immunoglobulin G | 6 | 2025 | 886 | 0.920 |
Why?
| | B-Lymphocytes | 3 | 2025 | 847 | 0.910 |
Why?
| | Immune System Diseases | 1 | 2025 | 39 | 0.900 |
Why?
| | Germinal Center | 1 | 2025 | 58 | 0.900 |
Why?
| | Antigens, Viral | 3 | 2021 | 180 | 0.890 |
Why?
| | Laboratory Proficiency Testing | 2 | 2021 | 10 | 0.870 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2024 | 86 | 0.850 |
Why?
| | Immunophenotyping | 1 | 2024 | 321 | 0.800 |
Why?
| | Killer Cells, Natural | 2 | 2024 | 446 | 0.790 |
Why?
| | Immunoassay | 3 | 2021 | 114 | 0.780 |
Why?
| | Convalescence | 1 | 2021 | 18 | 0.710 |
Why?
| | Allergy and Immunology | 1 | 2021 | 43 | 0.680 |
Why?
| | Pathology, Clinical | 1 | 2020 | 37 | 0.680 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2020 | 44 | 0.680 |
Why?
| | Blood Donors | 1 | 2021 | 103 | 0.640 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 97 | 0.640 |
Why?
| | Interferon-gamma | 3 | 2022 | 790 | 0.600 |
Why?
| | Coronavirus Infections | 2 | 2021 | 359 | 0.600 |
Why?
| | Antibody Specificity | 1 | 2018 | 189 | 0.580 |
Why?
| | Spike Glycoprotein, Coronavirus | 5 | 2022 | 107 | 0.570 |
Why?
| | Betacoronavirus | 1 | 2020 | 268 | 0.550 |
Why?
| | Societies, Medical | 1 | 2021 | 820 | 0.520 |
Why?
| | Allergens | 2 | 2024 | 407 | 0.510 |
Why?
| | Immunotherapy | 1 | 2021 | 647 | 0.500 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 368 | 0.480 |
Why?
| | Hypersensitivity | 1 | 2018 | 256 | 0.470 |
Why?
| | Mycobacterium Infections, Nontuberculous | 3 | 2014 | 360 | 0.450 |
Why?
| | Sensitivity and Specificity | 5 | 2021 | 1950 | 0.450 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 88 | 0.420 |
Why?
| | Humans | 39 | 2025 | 137514 | 0.410 |
Why?
| | Nickel | 1 | 2013 | 64 | 0.400 |
Why?
| | Food Hypersensitivity | 1 | 2015 | 183 | 0.390 |
Why?
| | Dermatitis, Allergic Contact | 1 | 2013 | 73 | 0.380 |
Why?
| | Immunoglobulins, Intravenous | 3 | 2022 | 132 | 0.380 |
Why?
| | Leukocytes, Mononuclear | 2 | 2022 | 558 | 0.370 |
Why?
| | Immunologic Factors | 1 | 2013 | 239 | 0.370 |
Why?
| | Serologic Tests | 2 | 2021 | 54 | 0.350 |
Why?
| | Reproducibility of Results | 5 | 2025 | 3292 | 0.340 |
Why?
| | Common Variable Immunodeficiency | 2 | 2021 | 29 | 0.300 |
Why?
| | Pandemics | 3 | 2021 | 1619 | 0.290 |
Why?
| | Lupus Nephritis | 1 | 2025 | 63 | 0.230 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2025 | 95 | 0.230 |
Why?
| | CD56 Antigen | 1 | 2024 | 36 | 0.220 |
Why?
| | Phenotype | 3 | 2024 | 3205 | 0.220 |
Why?
| | Leukocyte Common Antigens | 1 | 2024 | 87 | 0.220 |
Why?
| | Immunization, Passive | 2 | 2022 | 90 | 0.220 |
Why?
| | Lymphocytes | 2 | 2024 | 395 | 0.210 |
Why?
| | Immunologic Techniques | 1 | 2023 | 40 | 0.210 |
Why?
| | Immunoglobulin A | 1 | 2025 | 210 | 0.210 |
Why?
| | Alveolitis, Extrinsic Allergic | 1 | 2024 | 97 | 0.200 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2021 | 849 | 0.200 |
Why?
| | Immunologic Memory | 1 | 2025 | 369 | 0.190 |
Why?
| | Pulmonary Alveolar Proteinosis | 1 | 2021 | 17 | 0.190 |
Why?
| | Male | 12 | 2025 | 67718 | 0.190 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2021 | 36 | 0.180 |
Why?
| | Cross Reactions | 1 | 2021 | 133 | 0.180 |
Why?
| | Precision Medicine | 1 | 2025 | 426 | 0.180 |
Why?
| | Monocytes | 1 | 2024 | 568 | 0.180 |
Why?
| | Transplantation Immunology | 1 | 2021 | 34 | 0.180 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 152 | 0.180 |
Why?
| | Vero Cells | 1 | 2021 | 67 | 0.180 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 99 | 0.180 |
Why?
| | Histocompatibility Testing | 1 | 2021 | 126 | 0.170 |
Why?
| | Microarray Analysis | 1 | 2021 | 116 | 0.170 |
Why?
| | Emergency Responders | 1 | 2021 | 36 | 0.170 |
Why?
| | Adult | 8 | 2025 | 37821 | 0.170 |
Why?
| | Hexosephosphates | 1 | 2020 | 5 | 0.170 |
Why?
| | Glycogen Storage Disease Type I | 1 | 2020 | 6 | 0.170 |
Why?
| | Nucleocapsid Proteins | 1 | 2020 | 24 | 0.170 |
Why?
| | Cholesterol Side-Chain Cleavage Enzyme | 1 | 2020 | 9 | 0.170 |
Why?
| | RNA, Viral | 2 | 2024 | 653 | 0.170 |
Why?
| | Group Processes | 1 | 2021 | 62 | 0.170 |
Why?
| | Female | 12 | 2025 | 73162 | 0.170 |
Why?
| | Coronavirus | 1 | 2021 | 45 | 0.170 |
Why?
| | Specimen Handling | 1 | 2022 | 178 | 0.170 |
Why?
| | Glucosides | 1 | 2020 | 44 | 0.170 |
Why?
| | Phosphorylation | 1 | 2025 | 1762 | 0.170 |
Why?
| | Pneumococcal Vaccines | 1 | 2021 | 145 | 0.170 |
Why?
| | Benzhydryl Compounds | 1 | 2020 | 73 | 0.160 |
Why?
| | Virtual Reality | 1 | 2021 | 62 | 0.160 |
Why?
| | Neutropenia | 1 | 2020 | 146 | 0.160 |
Why?
| | Predictive Value of Tests | 1 | 2025 | 2039 | 0.160 |
Why?
| | Interleukin-13 | 1 | 2020 | 149 | 0.160 |
Why?
| | Th2 Cells | 1 | 2020 | 176 | 0.150 |
Why?
| | Phenylalanine Ammonia-Lyase | 1 | 2018 | 1 | 0.150 |
Why?
| | Phenylketonurias | 1 | 2018 | 15 | 0.150 |
Why?
| | Plasma | 1 | 2020 | 213 | 0.150 |
Why?
| | Antigen-Antibody Complex | 1 | 2018 | 90 | 0.150 |
Why?
| | Immunomodulation | 1 | 2019 | 98 | 0.150 |
Why?
| | Multiple Sclerosis | 1 | 2024 | 454 | 0.150 |
Why?
| | Peanut Hypersensitivity | 1 | 2020 | 146 | 0.150 |
Why?
| | Skin Tests | 1 | 2018 | 101 | 0.150 |
Why?
| | Phosphoproteins | 1 | 2020 | 338 | 0.140 |
Why?
| | Gamma Rays | 1 | 2018 | 56 | 0.140 |
Why?
| | Transfusion Reaction | 1 | 2018 | 46 | 0.140 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 367 | 0.140 |
Why?
| | Autoimmune Diseases | 1 | 2021 | 459 | 0.140 |
Why?
| | Animals | 5 | 2025 | 37011 | 0.140 |
Why?
| | Lung Diseases | 2 | 2014 | 768 | 0.140 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2857 | 0.140 |
Why?
| | Drug Hypersensitivity | 1 | 2018 | 89 | 0.140 |
Why?
| | Antibodies | 1 | 2018 | 414 | 0.130 |
Why?
| | Motivation | 1 | 2021 | 571 | 0.130 |
Why?
| | Epoxy Resins | 1 | 2015 | 3 | 0.130 |
Why?
| | Genetic Testing | 1 | 2019 | 453 | 0.120 |
Why?
| | Aged | 4 | 2025 | 23798 | 0.120 |
Why?
| | Graft vs Host Disease | 1 | 2018 | 249 | 0.120 |
Why?
| | Listeriosis | 1 | 2016 | 70 | 0.120 |
Why?
| | B-Cell Activation Factor Receptor | 1 | 2015 | 13 | 0.120 |
Why?
| | Ultraviolet Rays | 1 | 2018 | 389 | 0.120 |
Why?
| | Recombinant Proteins | 1 | 2018 | 1357 | 0.120 |
Why?
| | Infant, Newborn | 2 | 2024 | 6059 | 0.120 |
Why?
| | Retrospective Studies | 2 | 2025 | 15628 | 0.120 |
Why?
| | Spirometry | 1 | 2015 | 281 | 0.110 |
Why?
| | Neutrophils | 1 | 2020 | 1238 | 0.110 |
Why?
| | Immune System | 1 | 2015 | 177 | 0.110 |
Why?
| | Interleukin-10 | 1 | 2016 | 302 | 0.110 |
Why?
| | Child, Preschool | 3 | 2024 | 11097 | 0.110 |
Why?
| | Occupational Diseases | 1 | 2015 | 157 | 0.110 |
Why?
| | Hematologic Tests | 1 | 2013 | 22 | 0.100 |
Why?
| | Algorithms | 1 | 2021 | 1702 | 0.100 |
Why?
| | Patch Tests | 1 | 2013 | 57 | 0.100 |
Why?
| | Rituximab | 1 | 2013 | 178 | 0.100 |
Why?
| | Pneumonia | 2 | 2015 | 638 | 0.100 |
Why?
| | Mycobacterium avium Complex | 1 | 2013 | 88 | 0.100 |
Why?
| | Cell Proliferation | 3 | 2018 | 2482 | 0.100 |
Why?
| | Nontuberculous Mycobacteria | 1 | 2014 | 204 | 0.100 |
Why?
| | Quality Improvement | 1 | 2020 | 1161 | 0.090 |
Why?
| | Seroepidemiologic Studies | 2 | 2023 | 163 | 0.090 |
Why?
| | Mutation | 2 | 2022 | 3964 | 0.090 |
Why?
| | Middle Aged | 4 | 2025 | 33355 | 0.090 |
Why?
| | Signal Transduction | 1 | 2025 | 5096 | 0.090 |
Why?
| | Transforming Growth Factor beta | 1 | 2013 | 480 | 0.080 |
Why?
| | Adolescent | 3 | 2025 | 21555 | 0.080 |
Why?
| | Infant | 1 | 2024 | 9467 | 0.080 |
Why?
| | Quality of Life | 1 | 2022 | 2870 | 0.080 |
Why?
| | Inflammation | 1 | 2021 | 2837 | 0.080 |
Why?
| | Lymphocyte Activation | 3 | 2020 | 1150 | 0.080 |
Why?
| | Time Factors | 1 | 2021 | 6817 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 2018 | 1999 | 0.080 |
Why?
| | Child | 3 | 2024 | 22037 | 0.080 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2015 | 2193 | 0.070 |
Why?
| | Young Adult | 4 | 2020 | 13243 | 0.070 |
Why?
| | Colorado | 3 | 2023 | 4521 | 0.060 |
Why?
| | Nephrocalcinosis | 1 | 2025 | 13 | 0.060 |
Why?
| | Cells, Cultured | 1 | 2013 | 4206 | 0.060 |
Why?
| | RNA, Messenger | 2 | 2024 | 2838 | 0.050 |
Why?
| | Kidney | 2 | 2025 | 1472 | 0.050 |
Why?
| | Autophagy-Related Proteins | 1 | 2022 | 46 | 0.050 |
Why?
| | Hyperplasia | 1 | 2022 | 175 | 0.050 |
Why?
| | Vesicular Transport Proteins | 1 | 2022 | 84 | 0.050 |
Why?
| | Immunogenicity, Vaccine | 1 | 2021 | 30 | 0.050 |
Why?
| | World Health Organization | 1 | 2022 | 122 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 167 | 0.050 |
Why?
| | Immunity | 1 | 2022 | 145 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 234 | 0.040 |
Why?
| | Aged, 80 and over | 1 | 2013 | 7593 | 0.040 |
Why?
| | Microspheres | 1 | 2021 | 137 | 0.040 |
Why?
| | Respiratory Burst | 1 | 2020 | 16 | 0.040 |
Why?
| | Lysosomal-Associated Membrane Protein 2 | 1 | 2020 | 30 | 0.040 |
Why?
| | Aminoglutethimide | 1 | 2020 | 5 | 0.040 |
Why?
| | Granulocytes | 1 | 2020 | 80 | 0.040 |
Why?
| | Drug Repositioning | 1 | 2020 | 36 | 0.040 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2020 | 74 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2022 | 288 | 0.040 |
Why?
| | Off-Label Use | 1 | 2020 | 52 | 0.040 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2020 | 138 | 0.040 |
Why?
| | Drug Resistance | 1 | 2020 | 170 | 0.040 |
Why?
| | Gene Knockout Techniques | 1 | 2020 | 116 | 0.040 |
Why?
| | Autophagy | 1 | 2022 | 282 | 0.040 |
Why?
| | Autoimmunity | 1 | 2025 | 907 | 0.040 |
Why?
| | Complement C4 | 1 | 2018 | 28 | 0.040 |
Why?
| | Phenylalanine | 1 | 2018 | 68 | 0.040 |
Why?
| | Furocoumarins | 1 | 2018 | 8 | 0.040 |
Why?
| | Enzyme Activation | 1 | 2020 | 816 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 5427 | 0.040 |
Why?
| | NF-kappa B | 1 | 2022 | 694 | 0.040 |
Why?
| | Transfection | 1 | 2020 | 948 | 0.040 |
Why?
| | Complement C3 | 1 | 2018 | 210 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2022 | 1242 | 0.030 |
Why?
| | Pilot Projects | 1 | 2021 | 1703 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2022 | 1167 | 0.030 |
Why?
| | Adoptive Transfer | 1 | 2016 | 224 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2022 | 10821 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2016 | 240 | 0.030 |
Why?
| | IgA Deficiency | 1 | 2015 | 6 | 0.030 |
Why?
| | Blood Transfusion | 1 | 2018 | 324 | 0.030 |
Why?
| | Cholangitis | 1 | 2015 | 20 | 0.030 |
Why?
| | Listeria monocytogenes | 1 | 2016 | 126 | 0.030 |
Why?
| | Hepatitis | 1 | 2015 | 48 | 0.030 |
Why?
| | Hypertrophy | 1 | 2015 | 134 | 0.030 |
Why?
| | Granuloma | 1 | 2015 | 91 | 0.030 |
Why?
| | Delayed Diagnosis | 1 | 2015 | 91 | 0.030 |
Why?
| | Sequence Alignment | 1 | 2015 | 345 | 0.030 |
Why?
| | Cell Line | 1 | 2020 | 2852 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 2016 | 344 | 0.030 |
Why?
| | Forced Expiratory Volume | 1 | 2015 | 532 | 0.030 |
Why?
| | Thymus Gland | 1 | 2015 | 313 | 0.030 |
Why?
| | Exons | 1 | 2015 | 349 | 0.030 |
Why?
| | Fibrillins | 1 | 2013 | 9 | 0.030 |
Why?
| | Marfan Syndrome | 1 | 2013 | 41 | 0.030 |
Why?
| | Sinusitis | 1 | 2015 | 221 | 0.020 |
Why?
| | Lung Transplantation | 1 | 2015 | 309 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2013 | 131 | 0.020 |
Why?
| | Recurrence | 1 | 2015 | 1060 | 0.020 |
Why?
| | Occupational Exposure | 1 | 2015 | 342 | 0.020 |
Why?
| | Blood Glucose | 1 | 2020 | 2183 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 7598 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2016 | 3020 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2016 | 4295 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2013 | 3546 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2016 | 5792 | 0.010 |
Why?
| | United States | 1 | 2021 | 14696 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2015 | 5772 | 0.010 |
Why?
| | Risk Factors | 1 | 2014 | 10356 | 0.010 |
Why?
| | Mice | 1 | 2016 | 17843 | 0.010 |
Why?
|
|
Knight's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|